ARTICLE | Clinical News

JNJ reports data from Procrit CHOIR trial

April 21, 2006 12:55 AM UTC

Johnson & Johnson (JNJ) said that data from the CHOIR trial of its Procrit epoetin alfa showed a significantly higher composite incidence of mortality and cardiovascular events for patients treated to a hemoglobin level that was higher than that recommended by the product's label. Procrit's label recommends hemoglobin levels of 10-12 g/dl in anemia patients with chronic kidney disease who were not on dialysis, which is in-line with National Kidney Foundation guidelines that recommend treating patients to a range of 11-12 g/dl. ...